TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell

Pathology Research and Practice

Volumn 206, Issue 9, 2010, Pages 631-641

  Chen, Gang ^a   Rong, Minhua ^a   Luo, Dianzhong ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatocellular Carcinoma (HCC); Neutralization antibody (Ab); Proliferation; TNFRSF6B

Indexed keywords

ANTINEOPLASTIC AGENT; DECOY RECEPTOR 3; DECOY RECEPTOR 3 NEUTRALIZING ANTIBODY; MESSENGER RNA; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIGRATION INHIBITION; MITOSIS INHIBITION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; DNA FRAGMENTATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LIVER NEOPLASMS; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77956011978     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.05.011     Document Type: Article

References (27)

1. Ozören N., El-Deiry W.S. Cell surface Death Receptor signaling in normal and cancer cells. Semin. Cancer Biol. 2003, 13:135-147.
2. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
3. Wang S., El-Deiry W.S. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003, 22:8628-8633.
4. Ohshima K., Haraoka S., Sugihara M., Suzumiya J., Kawasaki C., Kanda M., et al. Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas. Cancer Lett. 2000, 160:89-97.
5. Chang P.M., Chen P.M., Hsieh S.L., Tzeng C.H., Liu J.H., Chiou T.J., et al. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome. Int. J. Oncol. 2008, 33:549-554.
6. Roth W., Isenmann S., Nakamura M., Platten M., Wick W., Kleihues P., et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 2001, 61:2759-2765.
7. Arakawa Y., Tachibana O., Hasegawa M., Miyamori T., Yamashita J., Hayashi Y. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol. 2005, 109:294-298.
8. Wu Y., Han B., Sheng H., Lin M., Moore P.A., Zhang J., et al. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int. J. Cancer 2003, 105:724-732.
9. Tsuji S., Hosotani R., Yonehara S., Masui T., Tulachan S.S., Nakajima S., et al. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma. Int. J. Cancer 2003, 106:17-25.
10. Ibrahim S.M., Ringel J., Schmidt C., Ringel B., Müller P., Koczan D., et al. Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death. Pancreas 2001, 23:72-79.
11. Chen G., Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl. Med. J. India 2008, 21:275-278.
12. Shen H.W., Gao S.L., Wu Y.L., Peng S.Y. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J. Gastroenterol. 2005, 11:5926-5930.
13. Fujita Y., Sakakura C., Shimomura K., Nakanishi M., Yasuoka R., Aragane H., et al. Chromosome arm 20q gains and other genomic alterations in esophageal squamous cell carcinoma, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Hepatogastroenterology 2003, 50:1857-1863.
14. Li H., Zhang L., Lou H., Ding I., Kim S., Wang L., et al. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am. J. Clin. Pathol. 2005, 124:282-287.
15. Bai C., Connolly B., Metzker M.L., Hilliard C.A., Liu X., Sandig V., et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:1230-1235.
16. Chen G., Luo D. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Upsala J. Med. Sci. 2008, 113:297-304.
17. Gill R.M., Ni J., Hunt J.S. Differential expression of LIGHT and its receptors in human placental villi and amniochorion membranes. Am. J. Pathol. 2002, 161:2011-2017.
18. Simon I., Liu Y., Krall K.L., Urban N., Wolfert R.L., Kim N.W., et al. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol. Oncol. 2007, 106:112-118.
19. Migone T.S., Zhang J., Luo X., Zhuang L., Chen C., Hu B., et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002, 16:479-492.
20. Yu K.Y., Kwon B., Ni J., Zhai Y., Ebner R., Kwon B.S.Y., et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 1999, 274:13733-13736.
21. Wan X., Shi G., Semenuk M., Zhang J., Wu J. DcR3/TR6 modulates immune cell interactions. J. Cell. Biochem. 2003, 89:603-612.
22. Yang C.R., Hsieh S.L., Teng C.M., Ho F.M., Su W.L., Lin W.W. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action. Cancer Res. 2004, 64:1122-1129.
23. Hsu T.L., Chang Y.C., Chen S.J., Liu Y.J., Chiu A.W., Chio C.C., et al. Modulation of dendritic cell differentiation and maturation by decoy receptor 3. J. Immunol. 2002, 168:4846-4853.
24. Wu S.F., Liu T.M., Lin Y.C., Sytwu H.K., Juan H.F., Chen S.T., et al. Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication. J. Leukoc. Biol. 2004, 75:293-306.
25. Yang C.R., Hsieh S.L., Ho F.M., Lin W.W. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J. Immunol. 2005, 174:1647-1656.
26. Abou-Alfa G.K., Venook A.P. The impact of new data in the treatment of advanced hepatocellular carcinoma. Curr. Oncol. Rep. 2008, 10:199-205.
27. Gish R.G., Baron A. Hepatocellular carcinoma (HCC): current and evolving therapies. IDrugs 2008, 11:198-203.